Parkinson's Disease — Visual Function During Gait in Parkinson's Disease: Impact of Cognition and Response to Visual Cues
Citation(s)
Galna B, Lord S, Daud D, Archibald N, Burn D, Rochester L Visual sampling during walking in people with Parkinson's disease and the influence of environment and dual-task. Brain Res. 2012 Sep 14;1473:35-43. doi: 10.1016/j.brainres.2012.07.017. Epub 2012 Jul 20.
Lord S, Galna B, Coleman S, Yarnall A, Burn D, Rochester L Cognition and gait show a selective pattern of association dominated by phenotype in incident Parkinson's disease. Front Aging Neurosci. 2014 Oct 21;6:249. doi: 10.3389/fnagi.2014.00249. eCollection 2014.
Stuart S, Alcock L, Galna B, Lord S, Rochester L The measurement of visual sampling during real-world activity in Parkinson's disease and healthy controls: a structured literature review. J Neurosci Methods. 2014 Jan 30;222:175-88. doi: 10.1016/j.jneumet
Stuart S, Galna B, Lord S, Rochester L, Godfrey A Quantifying saccades while walking: validity of a novel velocity-based algorithm for mobile eye tracking. Conf Proc IEEE Eng Med Biol Soc. 2014;2014:5739-42. doi: 10.1109/EMBC.2014.6944931.
Stuart S, Galna B, Lord S, Rochester L A protocol to examine vision and gait in Parkinson's disease: impact of cognition and response to visual cues. Version 2. F1000Res. 2015 Nov 30 [revised 2016 Jan 1];4:1379. doi: 10.12688/f1000research.7320.2. eColle
Stuart S, Hickey A, Galna B, Lord S, Rochester L, Godfrey A iTrack: instrumented mobile electrooculography (EOG) eye-tracking in older adults and Parkinson's disease. Physiol Meas. 2017 Jan;38(1):N16-N31. doi: 10.1088/1361-6579/38/1/N16. Epub 2016 Dec 12
Stuart S, Lord S, Hill E, Rochester L Gait in Parkinson's disease: A visuo-cognitive challenge. Neurosci Biobehav Rev. 2016 Mar;62:76-88. doi: 10.1016/j.neubiorev.2016.01.002. Epub 2016 Jan 7. Review.
Visual Function During Gait in Parkinson's Disease: Impact of Cognition and Response to Visual Cues
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
